Table 3.
Association Between Fluid and Number of Injections
| Ref | Study Design | Risk of Bias | Treatment | Protocol | Previous Treatments | Treatment Arm | N | No. of Injections | Time Point |
| Curry et al 201742 | Open-label | Mod | AFL | PRN | RAN | Eyes with IRF Eyes with SRF |
9 11 |
Injection frequency 46 days (P = 0.02) Injection frequency 41 days (P = 0.10) |
12 months |
| Dervenis et al 201624 | Observational | Low | RAN | PRN | Treatment-naive | SRF No SRF IRF No IRF |
42 20 32 30 |
3.9 3.3 3.7 3.9 |
12 months |
| Ersoy et al 201432 | Observational | Low | RAN or BEV | PRN | Mixed | Persistent SRF No persistent SRF |
14 16 |
7.1 (2.6) 5.4 (1.8) |
12 months |
| Guymer et al 201911 | RCT | Low | RAN | T&E | Treatment-naive | “Intensive” not tolerating SRF or IRF “Relaxed” tolerating SRF ≤200 µm “Intensive” not tolerating SRF or IRF “Relaxed” tolerating SRF ≤200 µm |
BL: 349 | 9.5 (2.6) 8.9 (2.3)* 17 (6.5) 15.8 (5.9)* *P = 0.001 relaxed vs. intensive arm |
12 months 24 months |
| Regillo et al 201517 | RCT post hoc | Low | RAN | PRN | Treatment-naive | SRF thickness >118.25 µm SRF thickness ≤118.25 µm |
117 134 |
8.9 7.3 |
12 months |
| Ritter et al 201418 | RCT | Low | RAN or RAN + PDT | PRN | Treatment-naive | With SRF Without SRF With IRF Without IRF |
82 75 40 55 60 69 62 61 |
RAN+PDT: 5.3 (2.2) RAN: 5.6 (2.4) RAN+PDT: 4.4 (2.3)* RAN: 4.8 (1.8) *P < 0.01 vs. with SRF RAN + PDT: 5.0 (2.3) RAN: 5.2 (2.0) RAN + PDT: 4.9 (2.2) RAN: 5.3 (2.4) |
12 months |
AFL, aflibercept; BEV, bevacizumab; BL, baseline; IRF, intraretinal fluid; Mod, moderate; PDT, photodynamic therapy; PRN, pro re nata; RAN, ranibizumab; RCT, randomized controlled trial; T&E, treat-and-extend.